{"id":384649,"date":"2020-11-19T01:03:01","date_gmt":"2020-11-19T06:03:01","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384649"},"modified":"2020-11-19T01:03:01","modified_gmt":"2020-11-19T06:03:01","slug":"vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/","title":{"rendered":"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with <strong>Veltassa<sup>\u00ae<\/sup><\/strong> agreement <\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><strong>Veltassa<\/strong><sup>\u00ae <\/sup><strong>is a well-tolerated<\/strong><sup><b>1 <\/b><\/sup><strong>and effective<\/strong><sup><b>2 <\/b><\/sup><strong>oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data<\/strong><\/li>\n<li><strong>Veltassa<\/strong><sup>\u00ae <\/sup><strong>will benefit from Fresenius Kabi\u2019s market-leading nephrology patient access in China alongside Velphoro<\/strong><b><sup>\u00ae <\/sup><strong>and Venofer<\/strong><\/b><sup>\u00ae<\/sup><\/li>\n<li><strong>China shows high prevalence of Chronic Kidney Disease (CKD) and heart failure<\/strong><sup><b>3<\/b><\/sup>\u00a0\n<\/li>\n<\/ul>\n<p>ST GALLEN, Switzerland &amp; BAD HOMBURG, Germany&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:\n<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20201118005914\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201118005914\/en\/<\/a><\/p>\n<p>\nVifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa<sup>\u00ae<\/sup> for the treatment of hyperkalemia in the People\u2019s Republic of China. Under the agreement, Fresenius Kabi will have the exclusive right to distribute and sell Veltassa<sup>\u00ae<\/sup> across China.\n<\/p>\n<p>\nStefan Schulze, CEO of Vifor Pharma Group comments, \u201cWe are delighted to expand VFMCRP\u2019s collaboration with Fresenius Kabi. There is a high prevalence of CKD and heart failure in China<sup>3<\/sup> and hyperkalemia is one of the most common complications associated with these two conditions. As a result there is a high demand for an effective, proven hyperkalemia treatment. The excellent commercial infrastructure, the well established relationships in nephrology and our existing successful collaboration make Fresenius Kabi our partner of choice to provide Veltassa<sup>\u00ae<\/sup> to patients.\u201d\n<\/p>\n<p>\nOskar Haszonits, President Region Asia Pacific of Fresenius Kabi said, \u201cThis agreement is an important step in intensifying our collaboration and relationship with VFMCRP in nephrology. We believe Veltassa<sup>\u00ae<\/sup> has the potential to provide many benefits to patients across the country, and we look forward to adding it to our portfolio and working with VFMCRP.\u201d\n<\/p>\n<p>\nHyperkalemia is a serious medical condition characterized by elevated levels of potassium in the blood and can be associated with life-threatening consequences. Patients with CKD and heart failure, especially those treated with RAAS (renin-angiotensin-aldosterone system) inhibitors are at particular risk of developing hyperkalemia. As a consequence, RAASi therapy, the cornerstone of treatment for CKD and heart failure, is often reduced or discontinued, compromising cardio-renal protection. By bringing Veltassa<sup>\u00ae<\/sup> to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.\n<\/p>\n<p>\nFresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. In China, the company is among the top 10 multinational pharmaceutical companies, being a market leader in clinical nutrition, anesthesia and nephrology. Fresenius Kabi has around 6,000 employees in China.\n<\/p>\n<p>\nBoth parties have agreed to not disclose financial terms of the collaboration.\n<\/p>\n<p><b>Vifor Pharma Group<\/b> is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).<br \/>\n<br \/>For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.viforpharma.com&amp;esheet=52331235&amp;newsitemid=20201118005914&amp;lan=en-US&amp;anchor=viforpharma.com&amp;index=1&amp;md5=33c99f346581aca40324d5910223fa76\">viforpharma.com<\/a><\/p>\n<p><b>Fresenius Kabi<\/b> is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company\u2019s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi\u2019s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.\n<\/p>\n<p>\nWith its corporate philosophy of &#8220;caring for life&#8221;, the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.<br \/>\n<br \/>For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fresenius-kabi.com%2F&amp;esheet=52331235&amp;newsitemid=20201118005914&amp;lan=en-US&amp;anchor=www.fresenius-kabi.com&amp;index=2&amp;md5=1a8d90ec1bfd04eedd8ee21d1fe43f92\">www.fresenius-kabi.com<\/a>.\n<\/p>\n<p><b>About Hyperkalemia<br \/>\n<br \/><\/b>Approximately 73% of advanced Chronic Kidney Disease (CKD) and 40% of chronic heart failure patients may be at risk of elevated blood potassium levels<sup>4<\/sup>. Hyperkalemia can cause abnormal heart rhythms and even sudden death<sup>5<\/sup>. There are often no warning signs, meaning a person can unknowingly experience spikes in potassium levels recurrently and be at risk for these cardiac events. Some medicines that are often prescribed to people with CKD and heart failure to help delay progression of their underlying disease and reduce mortality can cause hyperkalemia as a side effect. These may include RAASi such as angiotensin receptor blockers (ARBs), aldosterone antagonists (AAs) and angiotensin converting-enzyme (ACE) inhibitors as well as angiotensin II receptor\/neprilysin inhibitors (ARNI).\n<\/p>\n<p><b>About Veltassa<sup>\u00ae<br \/>\n<br \/><\/sup><\/b>Veltassa<sup>\u00ae<\/sup> is a potassium binder approved for the treatment of hyperkalemia. Veltassa\u00ae was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium.Veltassa\u00ae should not replace emergency treatment for life-threatening hyperkalemia. Made in powder form, Veltassa\u00ae is mixed with water and taken once a day with or without food. Veltassa\u00ae is consisting of smooth, spherical, uniform microbeads too large to be absorbed, thus protecting the gastrointestinal tract. Veltassa\u00ae works primarily in the lumen of the colon where potassium concentration is highest, and the residence time of the polymer is the longest. The potassium is then excreted from the body through the normal excretion process.\n<\/p>\n<hr \/>\n<p><sup>1<\/sup> Veltassa<sup>\u00ae<\/sup> EU SmPC 2019<br \/>\n<br \/><sup>2<\/sup> Agarwal R, et al. Lancet 2019;394:1540\u201350.<br \/>\n<br \/><sup>3<\/sup> Zhang et al. Lancet. 2012 Mar 3;379(9818):815-22; Guo et al. Int J Environ Res Public Health 2016; 13: E770. Guo et al. Curr Cardiol Rev. 2013 May; 9(2): 112\u2013122.<br \/>\n<br \/><sup>4<\/sup> Rosano GCM, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2018;4:180-188.<br \/>\n<br \/><sup>5<\/sup> Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J. 2001;77:759-764.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201118005914\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201118005914\/en\/<\/a><\/span><\/p>\n<p><b>Media Relations<br \/>\n<\/b><br \/>Nathalie Ponnier<br \/>\n<br \/>Global Head Corporate Communications<br \/>\n<br \/>+41 79 957 96 73<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@viforpharma.com\">media@viforpharma.com<br \/>\n<\/a><\/p>\n<p><b>Investor Relations<br \/>\n<\/b><br \/>Julien Vignot<br \/>\n<br \/>Head of Investor Relations<br \/>\n<br \/>+41 58 851 66 90<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@viforpharma.com\">investors@viforpharma.com<br \/>\n<\/a><\/p>\n<p>Fresenius Contact:<br \/>\n<br \/><b>Media Relations<br \/>\n<\/b><br \/>Martin Kunze<br \/>\n<br \/>Corporate Communications<br \/>\n<br \/>Fresenius SE &amp; Co. KGaA<br \/>\n<br \/>Else-Kr\u00f6ner-Str. 1<br \/>\n<br \/>61352 Bad Homburg, Germany<br \/>\n<br \/>+49 6172 60 82 115<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:martin.kunze@fresenius.com\">martin.kunze@fresenius.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Asia Pacific Switzerland Europe China Germany<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Hospitals Pharmaceutical Health Cardiology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201118005914\/en\/839984\/3\/Vifor_Pharma_Corporate_Design_VFMCRP_Logo_rgb.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201118005914\/en\/839999\/3\/FK_logo_viewimage.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement Veltassa\u00ae is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data Veltassa\u00ae will benefit from Fresenius Kabi\u2019s market-leading nephrology patient access in China alongside Velphoro\u00ae and Venofer\u00ae China shows high prevalence of Chronic Kidney Disease (CKD) and heart failure3\u00a0 ST GALLEN, Switzerland &amp; BAD HOMBURG, Germany&#8211;(BUSINESS WIRE)&#8211; Regulatory News: This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20201118005914\/en\/ Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa\u00ae for the treatment of hyperkalemia in the People\u2019s Republic of China. Under the agreement, Fresenius Kabi will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384649","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement Veltassa\u00ae is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data Veltassa\u00ae will benefit from Fresenius Kabi\u2019s market-leading nephrology patient access in China alongside Velphoro\u00ae and Venofer\u00ae China shows high prevalence of Chronic Kidney Disease (CKD) and heart failure3\u00a0 ST GALLEN, Switzerland &amp; BAD HOMBURG, Germany&#8211;(BUSINESS WIRE)&#8211; Regulatory News: This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20201118005914\/en\/ Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa\u00ae for the treatment of hyperkalemia in the People\u2019s Republic of China. Under the agreement, Fresenius Kabi will &hellip; Continue reading &quot;VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T06:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement\",\"datePublished\":\"2020-11-19T06:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/\"},\"wordCount\":1118,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/\",\"name\":\"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-19T06:03:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/","og_locale":"en_US","og_type":"article","og_title":"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement - Market Newsdesk","og_description":"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement Veltassa\u00ae is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data Veltassa\u00ae will benefit from Fresenius Kabi\u2019s market-leading nephrology patient access in China alongside Velphoro\u00ae and Venofer\u00ae China shows high prevalence of Chronic Kidney Disease (CKD) and heart failure3\u00a0 ST GALLEN, Switzerland &amp; BAD HOMBURG, Germany&#8211;(BUSINESS WIRE)&#8211; Regulatory News: This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20201118005914\/en\/ Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa\u00ae for the treatment of hyperkalemia in the People\u2019s Republic of China. Under the agreement, Fresenius Kabi will &hellip; Continue reading \"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T06:03:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement","datePublished":"2020-11-19T06:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/"},"wordCount":1118,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/","name":"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-19T06:03:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005914r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vfmcrp-and-fresenius-kabi-expand-collaboration-in-nephrology-in-china-with-veltassa-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa\u00ae agreement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384649"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384649\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}